Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accumulated Expenses: 2016-2024

Historic Accumulated Expenses for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $10.6 million.

  • UroGen Pharma's Accumulated Expenses rose 23.09% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 23.09%. This contributed to the annual value of $10.6 million for FY2024, which is 2.26% down from last year.
  • As of FY2024, UroGen Pharma's Accumulated Expenses stood at $10.6 million, which was down 2.26% from $10.8 million recorded in FY2023.
  • UroGen Pharma's 5-year Accumulated Expenses high stood at $10.8 million for FY2023, and its period low was $6.9 million during FY2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $10.6 million (2024), whereas its average is $9.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 42.36% in 2020, then decreased by 27.28% in 2021.
  • Over the past 5 years, UroGen Pharma's Accumulated Expenses (Yearly) stood at $9.6 million in 2020, then declined by 27.28% to $6.9 million in 2021, then increased by 18.84% to $8.3 million in 2022, then surged by 30.97% to $10.8 million in 2023, then dropped by 2.26% to $10.6 million in 2024.